Europe Cell and Gene Therapy CDMO Market Size, Share By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4) and By Country - Trends, Analysis and Forecast till 2034

Europe Cell and Gene Therapy CDMO Market was valued at USD 2.8 billion in 2024 and is  expected to reach USD 24.3 Billion by 2034 growing at a CAGR of 28.50%

The European region is emerging as a vibrant center for innovation and progress in the realm of cell and gene therapy, with Contract Development and Manufacturing Organizations (CDMOs) playing a crucial role in propelling this transformative field forward. Marked by a swiftly expanding healthcare infrastructure, a burgeoning biotechnology sector, and growing investments in research and development, the European CDMO market for cell and gene therapy stands poised for substantial growth. Against a backdrop of increasing instances of genetic and rare diseases and the region's diverse and sizable patient population, there is a mounting demand for advanced therapeutic solutions. CDMOs in Europe are uniquely positioned to meet this demand, offering specialized knowledge, cutting-edge manufacturing capabilities, and strategic geographic advantages. Consequently, the European CDMO market presents an enticing opportunity for stakeholders in the biopharmaceutical industry to collaborate, innovate, and propel the development and commercialization of groundbreaking cell and gene therapies within this dynamic and rapidly evolving landscape.

Key Drivers of Target Market:

Prevalence of Rare Diseases

The prevalence of genetic and rare diseases is on the rise in Europe, driving the growth of the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market. This increasing awareness of such conditions has spurred a demand for innovative treatments capable of targeting their genetic origins. Cell and gene therapies represent promising options by addressing genetic abnormalities directly, potentially providing lasting or curative effects for patients. Consequently, biopharmaceutical firms in Europe are increasingly relying on CDMOs for their specialized knowledge in developing and producing these advanced therapies. CDMOs play a critical role in advancing the development and commercialization of cell and gene therapies by offering comprehensive services spanning process development, manufacturing, and quality assurance, thereby facilitating the efficient delivery of these transformative treatments to patients in need.

Technological Advancements

The Europe Cell and Gene Therapy CDMO market is experiencing growth fueled by continuous technological advancements. These innovations are instrumental in improving the development, manufacturing, and commercialization of cell and gene therapies, rendering them more efficient, scalable, and cost-effective. Technologies such as automation, high-throughput screening, gene editing tools like CRISPR-Cas9, and viral vector production systems have transformed various aspects of therapy development, enabling faster and more precise manufacturing processes. Integration of these cutting-edge technologies empowers CDMOs in Europe to address the increasing demand for therapies, foster innovation, and expedite the delivery of transformative treatments to patients throughout the region.

Restrains:

Lack of Skilled Workforce

Despite the promising growth prospects, the Europe Cell and Gene Therapy CDMO market faces a significant challenge posed by the lack of a skilled workforce. The specialized nature of cell and gene therapy manufacturing requires highly trained personnel with expertise in cell biology, molecular biology, bioprocessing, and other relevant fields. However, there is a scarcity of professionals with the necessary skill sets and experience to effectively navigate the complex manufacturing processes and regulatory requirements associated with these advanced therapies. This shortage of skilled workforce may impede the ability of CDMOs in the Europe region to scale operations, meet project timelines, and maintain consistent product quality. Addressing this workforce challenge through targeted training programs, collaboration with academic institutions, and talent development initiatives is crucial for overcoming this restraining factor and unlocking the full potential of the Europe Cell and Gene Therapy CDMO market.

The market is segmented based on Service Area, Indication, Phase and Country.

Europe Cell and Gene Therapy CDMO Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2023 to 2034. For the purpose of this study segmented the Europe Cell and Gene Therapy CDMO Market report based on Service Area, Indication, Phases, and Country:

Segmentation:

By Service Area:

• Cell Therapy

• Plasmid DNA
• Viral Vector
• Others    

By Indication:

• Cancer
• Cardiovascular Disease
• Infectious Disease
• Genetic Disorders
• Neurological Disorders

By Phases:

• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Country:

• UK
• Germany
• France
• Russia
• Italy
• Rest of Europe

The key players operating the Europe Cell and Gene Therapy CDMO Market include Catalent Inc., LONZA GROUP, RECIPHARM AB, Wuxi Advanced Therapies, Pfizer CentreOne, Charles River Laboratories International Inc., PATHEON INC., Almac Group, FUJIFILM DIOSYNTH BIOTECHNOLOGIES, PCI Pharma Services

• Catalent Inc., Inc. 
• LONZA GROUP
• RECIPHARM AB
• Wuxi Advanced Therapies
• Pfizer CentreOne
• Charles River Laboratories International Inc.
• PATHEON INC., INC.
• Almac Group
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• PCI Pharma Services